Oncology

News

Blackstone funds new trials of Sanofi's Sarclisa in myeloma

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development

News

Sour taste for Nektar as bempegaldesleukin flunks ph3 test

Four years ago, Bristol-Myers Squibb paid $1.85 billion upfront to claim rights to Nektar's bem

News

AZ, Merck get FDA okay for Lynparza as adjuvant breast cance...

The FDA has cleared AstraZeneca and Merck & Co's Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending its lead over pretenders to its PARP inhibitor crown.

News

Chasing rivals, Bayer files Nubeqa for new prostate cancer u...

Bayer has filed for approval to extend the use of its prostate cancer therapy Nubeqa as it tries to achieve labelling parity with rival drugs from Pfizer/Astellas and Johnson & Jonson,

News

NICE says no to Keytruda in triple-negative breast cancer

There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, accord

News

BMS' cash cow Revlimid faces first generic rivals in US

Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales

Blackstone funds new trials of Sanofi's Sarclisa in myeloma

Sour taste for Nektar as bempegaldesleukin flunks ph3 test

AZ, Merck get FDA okay for Lynparza as adjuvant breast cance...

Chasing rivals, Bayer files Nubeqa for new prostate cancer u...

NICE says no to Keytruda in triple-negative breast cancer

BMS' cash cow Revlimid faces first generic rivals in US

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

Oncology

Editor's Picks